Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
2.310
0.00 (0.00%)
At close: Sep 16, 2026, 4:00 PM EDT
2.320
+0.010 (0.43%)
After-hours: Sep 16, 2026, 7:30 PM EDT
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $420.59 million as of September 16, 2026. Its market cap has increased by 191.97% in one year.
Market Cap
420.59M
Enterprise Value
261.57M
1-Year Change
191.97%
Ranking
Category
Stock Price
$2.31
ChartMarket Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $420.59M, an increase of 318.68%. That is a compound annual growth rate of 28.37%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 16, 2026 | 420.59M | 49.99% |
| Dec 31, 2025 | 280.40M | -3.25% |
| Dec 31, 2024 | 289.83M | 3,596.14% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 23, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Cabaletta Bio | 439.97M |
| Artiva Biotherapeutics | 435.61M |
| Rezolute | 433.54M |
| Kyverna Therapeutics | 430.43M |
| Prothena Corporation | 427.64M |
| ARS Pharmaceuticals | 422.65M |
| C4 Therapeutics | 421.98M |
| Atea Pharmaceuticals | 419.47M |